SCHEMBL1047388

SCHEMBL1047388

C=CC(N=C=O)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.35
ALOX15 P16050 4/20 0.35
KDM4E B2RXH2 4/20 0.35
MAPT P10636 4/20 0.35
CYP3A4 P08684 4/20 0.35
MIF P14174 3/20 0.34
HPGD P15428 3/20 0.34
USP2 O75604 2/20 0.34
TP53 P04637 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 5/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 2/20 0.31
CYP2D6 P10635 1/20 0.31
SRC P12931 1/20 0.31
ALOX12 P18054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1162464 0.93 CYP2C19 (0.35) CYP2C19ALOX15KDM4EMAPTCYP3A4
Formic Acid SCHEMBL1162475 0.93 CYP2D6 (0.35) CYP2C19ALOX15KDM4EMAPTCYP3A4
SCHEMBL28429021 0.91 CYP2C19 (0.34) CYP2C19ALOX15KDM4EMAPTCYP3A4
Phosphonic Acid SCHEMBL1162520 0.91 CYP2C19 (0.34) CYP2C19ALOX15KDM4EMAPTCYP3A4
SCHEMBL5800479 0.86 PGK1 (0.31)
SCHEMBL4443347 0.80 MIF (0.52) CYP2C19ALOX15KDM4EMAPTCYP3A4
SCHEMBL29812875 0.80 CYP2D6 (0.35) MIFLMNATSHRCYP2D6SRC
SCHEMBL6889278 0.80 MIF (0.34) CYP2C19ALOX15KDM4EMAPTCYP3A4
SCHEMBL3519342 0.77 MIF (0.36) MIFMEN1KMT2A
SCHEMBL3258485 0.77 KDM4E (0.40) CYP2C19ALOX15KDM4EMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630784-B1 PREPARATION OF ISOCYANATOSILANES MOMENTIVE PERFORMANCE MAT INC (US) 2021-07-07 EP claimed
EP-3630784-A1 PREPARATION OF ISOCYANATOSILANES Momentive Performance Materials Inc. (US) 2020-04-08 EP claimed
CN-110691786-A Preparation of isocyanatosilanes 莫门蒂夫性能材料股份有限公司 2020-01-14 CN claimed
US-10266554-B2 Preparation of isocyanatosilanes MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2019-04-23 US claimed
WO-2018222486-A1 PREPARATION OF ISOCYANATOSILANES MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2018-12-06 WO claimed
US-20180346493-A1 PREPARATION OF ISOCYANATOSILANES MOMENTIVE PERFORMANCE MATERIALS INC. 2018-12-06 US claimed
CN-103554168-B Epoxy radicals silicone hydride, its preparation method and the curable compositions comprising it 莫门蒂夫性能材料股份有限公司 2017-07-18 CN claimed
US-8889800-B2 Terminal-modified difunctional sulfur-containing polymers, compositions thereof and methods of use PRC-DESOTO INTERNATIONAL, INC. (US) 2014-11-18 US claimed
US-20140255609-A1 TERMINAL-MODIFIED DIFUNCTIONAL SULFUR-CONTAINING POLYMERS, COMPOSITIONS THEREOF AND METHODS OF USE PRC-DESOTO INTERNATIONAL, INC. 2014-09-11 US claimed
EP-1534759-B1 MACROMER FORMING CATALYSTS JOHNSON & JOHNSON VISION CARE (US) 2009-09-09 EP claimed
EP-0907668-B1 AMPHIPHILIC, SEGMENTED COPOLYMER OF CONTROLLED MORPHOLOGY AND OPHTHALMIC DEVICES INCLUDING CONTACT LENSES MADE THEREFROM NOVARTIS AG (CH) 2001-09-19 EP claimed
US-6043328-A MOLDINGS, CONTACT LENSES, CORNEAL IMPLANTS OR BIOMEDICAL ARTICLES, NOVARTIS AG (CH) 2000-03-28 US claimed
EP-0826158-B1 POLYSILOXANE-POLYOL MACROMERS, THEIR PREPARATION AND THEIR USE NOVARTIS AG (CH) 1999-09-15 EP claimed
EP-0826158-A1 POLYSILOXANE-POLYOL MACROMERS, THEIR PREPARATION AND THEIR USE Novartis AG (CH) 1998-03-04 EP claimed
WO-1996036890-A1 POLYSILOXANE-POLYOL MACROMERS, THEIR PREPARATION AND THEIR USE NOVARTIS AG (CH) 1996-11-21 WO claimed
EP-0415123-B1 1-Phenylalkyl-3-phenylurea derivatives MITSUBISHI CHEM IND (JP) 1994-12-07 EP claimed
EP-0439059-B1 1-Phenylalkyl-3-phenylurea derivative MITSUBISHI CHEM IND (JP) 1994-08-24 EP claimed
EP-0439059-A2 1-Phenylalkyl-3-phenylurea derivative Mitsubishi Chemical Corporation (JP) 1991-07-31 EP claimed
EP-0415123-A2 1-Phenylalkyl-3-phenylurea derivatives Mitsubishi Chemical Corporation (JP) 1991-03-06 EP claimed
US-4430326-A Method of diminishing glucose levels resulting from endogenous glucagon UNIVERSITY PATENTS, INC. (US) 1984-02-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346493-A1 PREPARATION OF ISOCYANATOSILANES IDH3A, IDH2, IDH1 CYP2C19 1757/4885ALOX15 3458/4885KDM4E 1663/4885
US-10266554-B2 Preparation of isocyanatosilanes IDH3A, IDH2, IDH1 CYP2C19 1757/4885ALOX15 3458/4885KDM4E 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.